|
|
|
|
|
by wjnc
731 days ago
|
|
(As a though experiment) The problem would be how to combine shareholder capitalism with post hoc lowering of prices. Why should the shareholders Novo accept less returns on their bet, in order to give Americans a better price than 'the US' with all it's market power (or lack thereof considering their institutional arrangements) can bargain for? My opinion: The US could obviously change their institutional arrangements and get lower prices for patients (plus the shortages that go along with low prices), but this change would face stiff opposition in Congress from those gaining from the current status quo. You get what you pay for. Massive prices, and all the preferential treatment of suppliers and those involved in the supply chains that money can buy. |
|